IRIS
RENDA, GIULIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.678
AS - Asia 5.046
EU - Europa 4.232
SA - Sud America 860
AF - Africa 76
Continente sconosciuto - Info sul continente non disponibili 13
OC - Oceania 3
Totale 16.908
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.539
SG - Singapore 2.204
CN - Cina 1.243
BR - Brasile 715
IE - Irlanda 690
UA - Ucraina 641
IT - Italia 616
RU - Federazione Russa 598
VN - Vietnam 542
TR - Turchia 502
SE - Svezia 493
GB - Regno Unito 324
DE - Germania 283
FR - Francia 209
FI - Finlandia 160
IN - India 123
HK - Hong Kong 94
AR - Argentina 65
CA - Canada 61
MX - Messico 58
PL - Polonia 51
BD - Bangladesh 44
IQ - Iraq 43
ID - Indonesia 36
JP - Giappone 34
AT - Austria 30
NL - Olanda 29
ZA - Sudafrica 28
IR - Iran 27
EC - Ecuador 24
BE - Belgio 22
ES - Italia 22
PK - Pakistan 19
KR - Corea 18
EG - Egitto 16
LT - Lituania 15
CO - Colombia 14
VE - Venezuela 14
JO - Giordania 13
PH - Filippine 13
UZ - Uzbekistan 13
PY - Paraguay 11
AE - Emirati Arabi Uniti 10
EU - Europa 10
CL - Cile 9
CZ - Repubblica Ceca 9
IL - Israele 9
NP - Nepal 9
SA - Arabia Saudita 7
KE - Kenya 6
MA - Marocco 6
MY - Malesia 6
OM - Oman 6
RO - Romania 6
KZ - Kazakistan 5
TN - Tunisia 5
CH - Svizzera 4
DK - Danimarca 4
DZ - Algeria 4
HU - Ungheria 4
JM - Giamaica 4
TT - Trinidad e Tobago 4
BH - Bahrain 3
CR - Costa Rica 3
GR - Grecia 3
GT - Guatemala 3
LB - Libano 3
SN - Senegal 3
UY - Uruguay 3
AU - Australia 2
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BN - Brunei Darussalam 2
BO - Bolivia 2
EE - Estonia 2
GE - Georgia 2
LV - Lettonia 2
MD - Moldavia 2
NE - Niger 2
PA - Panama 2
PE - Perù 2
PS - Palestinian Territory 2
RS - Serbia 2
SI - Slovenia 2
SY - Repubblica araba siriana 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AM - Armenia 1
AO - Angola 1
BG - Bulgaria 1
BJ - Benin 1
CG - Congo 1
CY - Cipro 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GD - Grenada 1
GY - Guiana 1
HN - Honduras 1
HR - Croazia 1
Totale 16.892
Salva come PNG Salva come JPEG
Città #
Singapore 1.590
Dallas 832
Jacksonville 756
San Jose 702
Dublin 671
Chandler 649
Ashburn 450
Princeton 337
Beijing 280
Izmir 224
Ho Chi Minh City 201
Nanjing 201
Southend 196
Los Angeles 161
Santa Clara 139
Hanoi 128
Altamura 118
Dearborn 117
Cambridge 116
Wilmington 112
Tongling 107
The Dalles 103
New York 96
Hong Kong 91
Nanchang 87
Ann Arbor 79
Buffalo 73
Council Bluffs 72
Chieti 69
São Paulo 66
Moscow 64
Redondo Beach 59
Munich 56
Pescara 43
Boardman 41
Hebei 39
Shenyang 39
Woodbridge 38
Kunming 35
Hefei 33
Tokyo 33
Warsaw 30
Orem 29
Tianjin 29
Montreal 27
Brooklyn 25
Haiphong 25
Washington 25
Augusta 24
Da Nang 24
Rio de Janeiro 24
Stockholm 24
Jiaxing 23
San Mateo 23
Brussels 22
Changsha 22
Grevenbroich 22
Johannesburg 22
Norwalk 22
Atlanta 21
Chicago 21
Houston 21
Lappeenranta 21
Mexico City 21
Leawood 20
London 20
Helsinki 19
Brasília 18
Toronto 18
Amsterdam 17
Ardabil 17
Camerino 17
Denver 17
Frankfurt am Main 17
Nuremberg 17
Teramo 17
Ankara 16
Baghdad 16
Hangzhou 16
Milan 16
Chennai 15
Dong Ket 15
Falls Church 15
Hải Dương 15
Kraków 15
Poplar 15
Seattle 15
Belo Horizonte 14
Guangzhou 14
Mumbai 14
Rome 14
Phoenix 13
Tashkent 13
Amman 12
Boston 12
Düsseldorf 12
Porto Alegre 12
Querétaro 12
Seoul 12
Turku 12
Totale 10.399
Salva come PNG Salva come JPEG
Nome #
Increased left atrial size in obese children and its association with insulin resistance: a pilot study 178
Effects of endurance, resistance and neuro-muscular electrical stimulation trainings to the anthropometric and functional mobility domains in elderly 168
Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial 165
Response to "Pharmacodynamic Interaction Between Aspirin and Ibuprofen: A Plausible Mechanism of Aspirin Resistance" 159
Optimal duration of antiplatelet therapy in recipients of coronary drug-eluting stents 152
La gestione del rischio tromboembolico nei pazienti con fibrillazione atriale in Italia: Dati al follow-up del Registro Europeo PREFER in AF 150
Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF - HF substudy 148
The Role of Multimodality Cardiovascular Imaging in Peripartum Cardiomyopathy 148
Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences 144
Failure in evoking the trigeminal cardiac reflex by mandibular stretching in healthy volunteers 143
Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease 143
Genetic determinants of blood pressure responses to caffeine drinking 141
Intracardiac thrombi during warfarin anticoagulation - A case report and a brief literature review 140
Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease 135
Echocardiographic screening for the anomalous aortic origin of coronary arteries 134
Surgical bleeding after pre-operative unfractionated heparin and low molecular weight heparin for coronary bypass surgery 133
Predictive Value of Echocardiographic Pulmonary to Left Atrial Ratio for In-Hospital Death in Patients with COVID-19 131
Awake systolic blood pressure variability correlates with target-organ damage in hypertensive subjects 131
Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs 128
Rapid decline of collateral circulation increases susceptibility to myocardial ischemia: the trade-off of successful percutaneous recanalization of chronic total occlusions 126
Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. nonselective COX-2 inhibitors 126
Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry 126
Aneurisma coronarico: scoperta generalmente casuale, prognosi sempre severa? 123
Genetic determinants of cognitive responses to caffeine drinking identified from a double-blind, randomized, controlled trial 123
Facilitated PCI: Rationale, current evidence, open questions and future directions 121
Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects 121
Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. non-selective COX-2 inhibitors 121
Contribution of Atrial Fibrillation to In-Hospital Mortality in Patients With COVID-19 121
Prognostic value of non-resistant and resistant masked uncontrolled hypertension detected by ambulatory blood pressure monitoring 121
Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects 120
Antithrombotic therapy after percutaneous coronary intervention of bifurcation lesions 120
Coffee: Health Effects 119
Risk of Atrial Fibrillation in Masked and White Coat Uncontrolled Hypertension 119
Edoxaban for the Prevention of Thromboembolism in Patients with Atrial Fibrillation and Bioprosthetic Valves 117
Cardiovascular Morbidity and Mortality Related to Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis 116
Cardiovascular and psychological reactivity after caffeine consumption 116
Thrombotic and hemorrhagic burden in women: Gender-related issues in the response to antithrombotic therapies 116
Increased thromboxane production by monocyte prostaglandin endoperoxide synthase-2 in patients with acute myocardial infarction (pubbl. su Suppl. Circulation) 115
Dose- Dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. 115
EFFECTS OF NIMESULIDE ON CONSTITUTIVE AND INDUCIBLE PROSTANOID BIOSYNTHESIS IN MAN. 115
Ambulatory blood pressure and risk of new-onset atrial fibrillation in treated hypertensive patients 115
Management of thromboembolic risk in patients with atrial fibrillation in Italy: baseline data from the PREFER in AF European Registry 114
Direct Oral Anticoagulants Halve Thromboembolic Events After Cardioversion of AF Compared With Warfarin 114
Incomplete suppression of platelet COX-1 activity associated with aspirin-resistant thromboxane biosynthesis in acute coronary syndromes 113
Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease 113
Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation 113
An early decline of collateral circulation parallels myocardial ischaemia during percutaneous coronary intervention: a drawback of recanalization of chronic coronary occlusions? 112
The legacy of ISCHEMIA 112
Platelet Indices and Risk of Death and Cardiovascular Events: Results from a Large Population-Based Cohort Study 111
Clinical outcome with different doses of low-molecular-weight heparin in patients hospitalized for COVID-19 111
Insulin-Requiring Versus Noninsulin-Requiring Diabetes and Thromboembolic Risk in Patients With Atrial Fibrillation: PREFER in AF 110
Blood pressure modifications after caffeine intake during cognitive tasks 109
Cardiovascular effects of caffeine during cognitive tasks 109
Prognostic Significance of Chest Imaging by LUS and CT in COVID-19 Inpatients: The ECOVID Multicenter Study 109
Autonomic nervous system dysfunction in obese children 108
The AVERROES Trial – Clinical Implications 108
Sex Implications in the Response to Anticoagulant Therapy in Atrial Fibrillation ∗ 108
Predialysis and Dialysis Therapies Differently Affect Nitric Oxide Synthetic Pathway in Red Blood Cells from Uremic Patients: Focus on Peritoneal Dialysis 108
Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy 107
Role of CES1 and ABCB1 Genetic Polymorphisms on Functional Response to Dabigatran in Patients with Atrial Fibrillation 106
Antithrombotic therapy in atrial fibrillation: state of the art and perspectives. 106
Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy - A pooled analysis from the PREFER in AF and PREFER in AF PROLONGATON registries 106
History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial 106
Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease 106
Celecoxib, ibuprofen and the antiplatelet effect of aspirin in patients with osteoarthritis and chronic stable angina 105
Systolic and diastolic dysfunction occurs in newly diagnosed patients with hypertension and high systolic blood pressure variability 105
Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe. 105
Enhanced thromboxane biosynthesis in patients with colorectal and lung cancer 105
Non-vitamin K Antagonist Oral Anticoagulants for Cardioversion in Atrial Fibrillation - An Updated Meta-analysis 105
INCREASED THROMBOXANE PRODUCTION BY MONOCYTE PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-2 IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION. 104
CHA2DS2VASc score and adverse outcomes in middle-aged individuals without atrial fibrillation 104
New anticoagulants for atrial fibrillation 103
Ruolo del fibrinogeno e della conta piastrinica sull’inibizione dell’aggregazione piastrinica da parte dei farmaci anti-glicoproteina IIbIIIa 103
The left atrial appendage: from embryology to prevention of thromboembolism 103
Nutrigenetics of blood pressure responses to coffee drinking 102
Predictive Value of Left Atrial and Ventricular Strain for the Detection of Atrial Fibrillation in Patients With Cryptogenic Stroke 100
Thromboembolic and bleeding risk in obese patients with atrial fibrillation according to different anticoagulation strategies 100
AF: current and forthcoming antithrombotic therapies 100
Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W 99
Effect of fibrinogen concentration and platelet count on the inhibitory effect of abciximab and tirofiban 99
Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A 'state-of-the-art' paper 99
Prognostic significance of noncardiac syncope in the general population: A systematic review and meta-analysis 99
Atrial and left atrial appendage thrombosis in patients with atrial fibrillation: from pathophysiology to treatment 99
A real-world multicenter study on left atrial appendage occlusion: The Italian multi-device experience 98
Measurements of thromboxane production and their clinical significance in coronary heart disease 98
Systolic blood pressure variability by non-invasive monitoring predicts intima-media thickness independent of absolute blood pressure levels 98
PrevenTion of contrast-inducEd nephropAThy with urinE alkalinization: the TEATE study design 98
Predictors of Mortality and Cardiovascular Outcome at 6 Months after Hospitalization for COVID-19 98
ENHANCED CORTISOL SECRETION DOES NOT CONTROL ASPIRIN-INSENSITIVE THROMBOXANE BIOSYNTHESIS IN PATIENTS WITH ACUTE CORONARY SYNDROMES 96
Case Report: Mitral Valve Involvement and First-Degree Atrial-Ventricular Block in Two Patients With Multisystem Inflammatory Syndrome in Children 96
Circadianicity of hemostatic function and coronary vasomotion 94
A comparison between unfractionated heparin and a low molecular weight heparin in cardiac surgery 94
A comparison between unfractioned heparin and a low molecular weight heparin in cardiac surgery 94
MECHANISMS OF ISOPROSTANE BIOSYNTHESIS IN HUMANS 93
Antithrombotic prophylaxis in the elderly with atrial fibrillation 93
Ex Vivo Antiplatelet Effects of Oral Anticoagulants 92
Systolic blood pressure response to coffee is modulated by alpha2B adrenergic receptor I/D polymorphism 92
Surgical bleeding after preoperative unfractionated heparin and low molecular weight heparin at coronary bypass surgery 92
Systolic and diastolic dysfunction occurs in newly diagnosed patients with hypertension and high systolic blood pressure variability 92
Antithrombotic management 92
Totale 11.471
Salva come PNG Salva come JPEG
Categoria #
all - tutte 68.243
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 68.243
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021282 0 0 0 0 0 0 0 0 0 102 142 38
2021/2022691 12 5 5 126 82 8 17 62 64 18 71 221
2022/20232.004 182 282 117 193 181 391 139 137 268 23 51 40
2023/2024961 75 17 57 11 51 299 221 46 11 29 30 114
2024/20252.732 168 442 348 83 61 96 88 124 314 192 303 513
2025/20266.667 485 291 1.271 995 624 390 977 422 739 473 0 0
Totale 17.563